Taiwan, China biopharmas to develop HCV treatment in 1st cross-straits deal
By Pearl Liu
Friday, November 11, 2016
SHANGHAI – Leaving politics aside, a Taiwanese company and a China counterpart plan to set up a $102 million joint venture to develop a dual drug, oral direct-acting antiviral treatment for chronic HCV.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.